USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: SAVARA, INC.
City: Austin
State: TX
Zip+4: 78746
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $524,251.00 3
SBIR Phase II $3,986,098.00 1

Award List:

A High Efficiency Corticosteroid Dry Powder Inhaler for Pediatric Use

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Taneli Jouhikainen – 785-550-0672
Award Amount: $184,148.00
Abstract:
DESCRIPTION (provided by applicant): Asthma is a chronic respiratory disease with a global human and economic burden on patients, and society. Asthma treatment mainly consists of inhaled corticosteroids and bronchodilators, which enable adult populations to function well despite the disease. Small… More

Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Taneli Jouhikainen – 512-632-7537
Award Amount: $149,750.00
Abstract:
DESCRIPTION (provided by applicant): Savara Inc. is developing a novel inhaled dry-powder form of vancomycin (AEROVANC) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection, initially in cystic fibrosis (CF) patients and subsequently in other high risk patient… More

Targeted nanoparticle gene therapy for lung cancer

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Taneli Jouhikainen – 512-632-7537
Award Amount: $190,353.00
Abstract:
DESCRIPTION (provided by applicant): Project Summary A transformational NanoNucleic delivery technology is being investigated by Savara Inc. as a promising first-in-class gene therapy candidate for lung cancer. A potent lung cancer therapy with fewer sideeffects is urgently needed due to the… More

Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: Taneli Jouhikainen – 512-614-1848
Award Amount: $3,986,098.00
Abstract:
DESCRIPTION (provided by applicant): Persistent respiratory methicillin-resistant Staphylococcus aureus (MRSA) infections have become increasingly common in cystic fibrosis (CF) patients, with a prevalence of almost 30% in CF patients in the US. This is concerning, as MRSA positivity is associated… More